

Shanghai Allink Biotherapeutics Co., Ltd. established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company's experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics.
Powered by a proprietary bispecific antibody platform and novel conjugation technology, AllinkBio develops next-generation BsADCs characterized by optimized drug-to-antibody ratios (DARs), enhanced hydrophilicity, and superior stability. The company's independent intellectual property portfolio underpins its technological advantages in the field.
Based in Shanghai's Zhangjiang Hi-Tech Park, AllinkBio has built a robust pipeline focused on oncology and immunology therapeutics. The company is rapidly advancing multiple lead candidates toward clinical stage in 2024.

Allink was established in 2023
Over 5 patents covering products and technology
Nearly 30 years of experience in biopharmaceutical and ADC R&D
More than 10 innovative pipelines
Experienced R&D team
Efficient execution
Proprietary platform
International collaboration experience

AllinkBio's leadership team brings over 20 years of extensive expertise in innovative drug development and corporate growth

Through continuous scientific innovation, we are committed to developing world-class bispecific antibodies and ADC drugs to address unmet medical needs globally

To innovate and develop cutting-edge products that enhance human health and well-being, while adhering to the highest standards of scientific excellence.

Innovation-driven, patient-centered and proactively collaborative.